NEW YORK, Sept. 18, 2020 /PRNewswire/ -- AIkido Pharma
Inc. (Nasdaq: AIKI) today announced that its work with research
partner, Cogia BioTech LTD (www.cogia.de), has delivered several
key updates on efforts to accelerate the study of PDA (Pancreatic
Ductal Adenocarcinoma) treatments. As previously reported, the
Company executed a Scientific Research Agreement with The
University of Texas Southwestern Medical
Center and Cogia to use machine learning to find genetic
markers in people that indicate an increased risk of developing
pancreatic cancer.
Cogia Biotech, a Big-data, Artificial Intelligence (AI), and
Machine Learning (ML) software company committed to using powerful
AI engines and algorithms to develop compelling outcomes in drug
development, released a comprehensive progress report to AIkido
which included:
- The identification of clusters of markers that interact in
signaling pathways affecting PDA survival.
- The development of products and tools to provide extensive
information on PDA markers to guide personalized medicine.
- The assembly of survival associations of individual markers
from ONCOLNC.org into sets that will help identify novel targets in
PDA.
- Information about gene and protein function in human PDA
patients and human PDA cancer cell lines to help prioritize
individual diagnostic markers.
Anthony Hayes, CEO of AIkido
stated, "We are extremely pleased with the progress that Cogia has
made in this research project, and are enthusiastic about their
continued efforts to develop panels of markers that will rapidly
identify patients who have initiated early events in pancreatic
cancer. Cogia's Diagnostic Assay Application and Prognostic Marker
Characterization Application products assemble essential
information on antibodies specific to the respective proteins for
more than 20,000 antibody reagents and utilizes the unsupervised
learning protocols of the Cogia AI/ML engine to identify clusters
of similarly expressed genes, and their association with PDA
subtypes. These tools establish the building blocks of what
we continue to believe will be an even broader set of usable
full-service products and tools for ongoing and more expanded PDA
diagnostics, prognostics, and therapeutics.
About AIkido
AIkido was initially formed in 1967 and is a biotechnology
company with a diverse portfolio of small-molecule anti-cancer
therapeutics. The Company's platform consists of patented
technology from leading universities and researchers and we are
currently in the process of developing an innovative therapeutic
drug platform through strong partnerships with world renowned
educational institutions, including The University of Texas at Austin and Wake Forest University. Our diverse pipeline of
therapeutics includes therapies for pancreatic cancer, acute
myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL). In
addition, we are constantly seeking to grow our pipeline to treat
unmet medical needs in oncology. The Company is also
developing a broad spectrum antiviral platform that may potentially
inhibit replication of multiple viruses including Influenza virus,
SARS-CoV (coronavirus), MERS-CoV, Ebolavirus and Marburg virus.
Contact:
Investor Relations:
Hayden IR
Brett Maas, Managing Partner
Phone: (646) 536-7331
Email: brett@haydenir.com
www.haydenir.com
AIkido:
Phone: 212-745-1373
Email: investorrelations@AIkido.com
www.AIkido.com
View original content to download
multimedia:http://www.prnewswire.com/news-releases/aikido-pharma-announces-update-on-its-use-of-artificial-intelligence-301133942.html
SOURCE AIkido Pharma Inc.